摘要
目的评价缬沙坦对高血压患者左心室肥厚及左心室舒张功能的影响。方法选原发性高血压并左心室肥厚患者48例,随机分为缬沙坦治疗组和硝苯地平缓释片治疗组(对照组),治疗6个月,控制收缩期血压低于或等于140mmHg(1mmHg=0.133kPa),舒张期血压低于或等于95mmHg。于治疗前、治疗3个月、6个月作体格检查、血生化及心脏超声检查,记录心率、收缩压、舒张压、左心室舒张末期内径、室间隔厚度、左心室后壁厚度、左心室射血分数、舒张早期和晚期最大速度比值(E/A比值),计算左心室重量指数。结果调整用药后两组患者血压均达目标值;治疗3个月后两组病人左心室重量指数和E/A即显示差异,但缺乏统计学意义;治疗6个月后缬沙坦治疗组的左心室重量指数和E/A比值较对照组改善明显,而两组治疗前后左心室射血分数均无明显变化。结论相对于硝苯地平缓释片,缬沙坦对于原发性高血压患者的左心室肥厚和左心室舒张功能有更明显的改善,这种受益是独立于其降压作用之外的。
Objectives To assess the effects of valsartan on left ventricular hypertrophy （LVH） and diastolic function in patients with essential hypertension （EHP）. Methods 48 patients of essential hypertension with LVH were divided randomly into two groups, the valsartan-treatment group and the nifedipine-treatment （control）group.The blood pressure of each patient was decreased. The destination of blood pressure reduction was sBP≤140 and/or dBP≤95 mm Hg. Before and after treatment 3 and 6 months, HR, sBP, dBP, LVDD, IVS, LVPW, LVEF, E/A ratio were measured. LVMI were calculated. Results The blood pressure of each patient was decreased to large titre. There were differences on LVMI and E/A ratio between two groups after 3 months. But there was no statistic significance. After 6 months the decrease of LVMI and elevation of E/A ratio in the valsartan-treatment group were more significant than that in nifedipine-treatment group. But there was no difference on LVEF in both groups before and after treatment. Conclusions Against nifedipine,valsartan is more effective for LVMI reduction and improvement of E/A ratio on LVH of the patients with EHP. This kind of benefit is not dependent on the effect of descent of blood pressure.
出处
《岭南心血管病杂志》
2005年第4期256-258,共3页
South China Journal of Cardiovascular Diseases
关键词
缬沙坦
原发性高血压
左心室肥厚
左心室舒张功能
Valsartan
Essential hypertension
Left ventricular hypertrophy
Diastolic function
